These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 17294849

  • 1. [Molecular portrait of breast cancer with sub-classification of breast tumor].
    Siegelmann-Danieli N, Stein ME, Wallach N.
    Harefuah; 2007 Jan; 146(1):48-52, 77-8. PubMed ID: 17294849
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Gene expression profiling of ER+ breast cancers: to discriminate the poor prognosis tumors or to define the most suitable treatment?].
    Chanrion M, Darbon JM.
    Bull Cancer; 2008 May; 95(5):513-8. PubMed ID: 18541515
    [Abstract] [Full Text] [Related]

  • 5. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX.
    Kaklamani V.
    Expert Rev Mol Diagn; 2006 Nov; 6(6):803-9. PubMed ID: 17140367
    [Abstract] [Full Text] [Related]

  • 9. The genomic profile of HER2-amplified breast cancers: the influence of ER status.
    Marchiò C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, Lord CJ, Hungermann D, Fenwick K, Tamber N, Mackay A, Palacios J, Sapino A, Buerger H, Ashworth A, Reis-Filho JS.
    J Pathol; 2008 Dec; 216(4):399-407. PubMed ID: 18810758
    [Abstract] [Full Text] [Related]

  • 10. Breast cancer stratification from analysis of micro-array data of micro-dissected specimens.
    Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, Ganesan S, Delisi C, Bhanot G.
    Genome Inform; 2007 Dec; 18():130-40. PubMed ID: 18546481
    [Abstract] [Full Text] [Related]

  • 11. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.
    J Clin Oncol; 2007 Nov 20; 25(33):5194-202. PubMed ID: 17954712
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.
    Oncol Rep; 2008 Mar 20; 19(3):651-6. PubMed ID: 18288397
    [Abstract] [Full Text] [Related]

  • 14. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
    Clin Cancer Res; 2007 Apr 15; 13(8):2329-34. PubMed ID: 17438091
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
    Van Laere S, Beissbarth T, Van der Auwera I, Van den Eynden G, Trinh XB, Elst H, Van Hummelen P, van Dam P, Van Marck E, Vermeulen P, Dirix L.
    Clin Cancer Res; 2008 Nov 15; 14(22):7452-60. PubMed ID: 19010862
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 19. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?
    Tang P, Skinner KA, Hicks DG.
    Diagn Mol Pathol; 2009 Sep 01; 18(3):125-32. PubMed ID: 19704256
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.